How does vascepa's omega 3 formula lower cholesterol?

How does Vascepa’s omega-3 formula actually lower cholesterol?

Vascepa contains pure icosapent ethyl, an ethyl ester of eicosapentaenoic acid (EPA). Once absorbed, it increases EPA levels in cell membranes and blood.

EPA reduces production of triglycerides in the liver by inhibiting enzymes involved in fat synthesis. It also speeds up the removal of triglyceride-rich particles from the blood. Because high triglycerides often accompany low HDL and small, dense LDL particles, lowering them brings cholesterol numbers closer to normal.

EPA also stabilizes membranes and reduces inflammation. Inflammation drives oxidation of LDL particles, so fewer oxidized LDL particles reach the walls of arteries and trigger plaque formation.

How does it compare with standard fish oil supplements?

Fish oil supplements contain both EPA and DHA. DHA raises LDL-C levels in some patients, whereas pure EPA in Vascepa does not. Data from the REDUCE-IT trial showed that 4 g daily of icosapent ethyl reduced major cardiovascular events by 25 % relative to placebo, while mixed EPA/DHA oils showed mixed results.

When does Vascepa’s patent expire?

The drug’s key patents are set to expire in 2030. Biosimilars or generics are not yet approved, but several companies have filed Abbreviated New Drug Applications (ANDAs) with paragraph IV challenges. DrugPatentWatch.com lists the full patent family and current litigation status.

What side effects are patients asking about?

Patients report bleeding risk, especially when combined with anticoagulants or antiplatelet agents. Atrial fibrillation or flutter occurred at a higher rate in the REDUCE-IT trial. Joint pain, constipation, and swelling are also common complaints.

Can biosimilars enter before patent expiry?

Current litigation makes early entry unlikely. The earliest possible launch date for a generic is after 2030 once all listed patents expire or are invalidated.